Literature DB >> 15907646

Oxycodone.

Eija Kalso1.   

Abstract

Oxycodone has been in clinical use since 1917. Parenteral oxycodone was used mainly for the treatment of acute postoperative pain whereas combinations, for example, oxycodone and acetaminophen, were used for moderate pain. Since the introduction of controlled-release oxycodone, it has been used to manage cancer-related pain and chronic non-cancer-related pain problems. Controlled studies have been performed in postoperative pain, cancer pain, osteoarthritis-related pain, and neuropathic pain due to postherpetic neuralgia and diabetic neuropathy. The pharmacodynamic effects of oxycodone are typical of a mu-opioid agonist. Oxycodone closely resembles morphine but it has some distinct differences, particularly in its pharmacokinetic profile. Being an old drug, the basic pharmacology of oxycodone has been a neglected field of research.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15907646     DOI: 10.1016/j.jpainsymman.2005.01.010

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  75 in total

1.  Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone.

Authors:  Juha Grönlund; Teijo I Saari; Nora M Hagelberg; Pertti J Neuvonen; Klaus T Olkkola; Kari Laine
Journal:  Br J Clin Pharmacol       Date:  2010-07       Impact factor: 4.335

2.  Oxycodone physical dependence and its oral self-administration in C57BL/6J mice.

Authors:  Rachel M Enga; Asti Jackson; M Imad Damaj; Patrick M Beardsley
Journal:  Eur J Pharmacol       Date:  2016-07-05       Impact factor: 4.432

3.  Comparison of oxycodone pharmacokinetics after buccal and sublingual administration in children.

Authors:  Hannu Kokki; Ilpo Rasanen; Merja Lasalmi; Sanna Lehtola; Veli-Pekka Ranta; Kari Vanamo; Ilkka Ojanperä
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 4.  Clinical pharmacology of analgesic medicines in older people: impact of frailty and cognitive impairment.

Authors:  Andrew J McLachlan; Sally Bath; Vasi Naganathan; Sarah N Hilmer; David G Le Couteur; Stephen J Gibson; Fiona M Blyth
Journal:  Br J Clin Pharmacol       Date:  2011-03       Impact factor: 4.335

5.  A pharmacokinetic and pharmacodynamic study of oral oxycodone in a human experimental pain model of hyperalgesia.

Authors:  Anne E Olesen; Richard Upton; David J R Foster; Camilla Staahl; Lona L Christrup; Lars Arendt-Nielsen; Asbjørn M Drewes
Journal:  Clin Pharmacokinet       Date:  2010-12       Impact factor: 6.447

6.  Nonclinical safety assessment of PF614: A novel TAAP prodrug of oxycodone for chronic pain indication.

Authors:  P S Joshi; N Sanakkayala; L Kirkpatrick; P S Terse
Journal:  Regul Toxicol Pharmacol       Date:  2019-07-27       Impact factor: 3.271

7.  [Oral therapy algorithm for the treatment of postoperative pain. A prospective observational study].

Authors:  E M Pogatzki-Zahn; J S Englbrecht; D Pöpping; R Boche; P K Zahn
Journal:  Schmerz       Date:  2013-02       Impact factor: 1.107

Review 8.  Cancer pain management: what's new?

Authors:  Jan Gaertner; Christine Schiessl
Journal:  Curr Pain Headache Rep       Date:  2013-04

9.  Adequacy assessment of oxycodone/paracetamol (acetaminophen) in multimodal chronic pain : a prospective observational study.

Authors:  Antonio Gatti; Alessandro Fabrizio Sabato; Annalisa Carucci; Laura Bertini; Massimo Mammucari; Roberto Occhioni
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

10.  Effects of Acute and Repeated Administration of Oxycodone and Naloxone-Precipitated Withdrawal on Intracranial Self-Stimulation in Rats.

Authors:  Jason M Wiebelhaus; D Matthew Walentiny; Patrick M Beardsley
Journal:  J Pharmacol Exp Ther       Date:  2015-10-21       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.